

August 20, 2021

## Announcements

### Dr. Alex Choi to Join Palliative Medicine

We are pleased to announce that Alex Choi, MD, who recently completed his fellowship in Hospice and Palliative Medicine at Yale, will join the faculty of the Palliative Care Program in October as an Instructor of Medicine (General Internal Medicine). Dr. Choi received his medical degree from the University of Illinois College of Medicine at Peoria and completed a Combined Internal Medicine/Pediatrics Residency at Stony Brook University Hospital.

In 2020, Dr. Choi received both the Excellence in Teaching by a Senior Resident Award and the


Department of Medicine Excellence in a Research Project Award. He has served on the Smilow Mortality Review Committee, was Vice Chair of the Yale Resident Fellow Senate Wellness Council, and a member of the Yale Resident Fellow Senate Education Council. His recent research has focused on palliative care in adolescents and young adults and clinical and ethical considerations in patients with advanced head and neck cancer.

### Closer to Free Moves Virtual

Based on recent data regarding COVID-19 and guidance from our medical team at Yale New Haven Health, we have made the difficult decision to return to a fully virtual ride for 2021. We know you share our disappointment in this news, but we also know that you also share in our belief that our community's health is more important than anything else.

The good news is that we are prepared to give you another rewarding virtual ride experience. A special Ride Week Website is currently under construction, complete with activities and opportunities to connect to the Closer to Free community. On Ride Weekend, you'll tune in for our powerful

Opening Ceremony broadcast before heading out to ride on your personal




from the desk of  
**Nita Ahuja, MD, MBA, FACS**  
Interim Director, Yale Cancer Center  
Interim Physician-in-Chief,  
Smilow Cancer Hospital

Yale  
NewHaven  
Health  
Smilow Cancer  
Hospital

Yale **CANCER**  
CENTER  
A Comprehensive Cancer Center Designated  
by the National Cancer Institute

## News Center

**Yale Scientists Reveal Molecular Pathway  
for Smarter Breast Cancer Drugs**



[Read More](#)

[Targeting Disparities In Colorectal Cancer](#)

[Screening](#)

route (or at home on your spin bike). If you have not yet registered for this year's Ride on September 11, please **join us!**

## Yale Cancer Center Grand Rounds

Grand Rounds attendance will now need to be submitted via text message each week if you wish to receive CME credit. Yale Cancer Center Grand Rounds remains open for anyone to join and watch via Zoom access. To record attendance for CME credit, you must first have an active account in Yale CloudCME®. If you do not have an active CME account but want to receive credit, please take a few minutes to **set up your account** in advance.

You will only be able to record your CME attendance beginning 15 minutes prior to Grand Rounds on Tuesdays at Noon, during Grand Rounds, or up to 30 minutes after. A unique ID number will be provided each week at the beginning of Grand Rounds, and then again at the end. You must first pair your phone with your account in Yale CloudCME®. To pair your phone, please text the email address you use for your Yale CME Profile to **203-442-9435**. You will receive a message that your phone number has been updated. This is a one-time requirement.

To record your attendance each week, text the unique ID number provided to **203-442-9435**. You will receive a message back that verifies your activity attendance has been recorded. The ID number will change each week. Please reach out to **Emily Montemerlo** with questions regarding this change.


## Notables

The **Breast Cancer Research Foundation (BCRF)** has awarded **Mehra Golshan, MD, MBA**, Professor of Surgery (Surgical Oncology), Deputy Chief Medical Officer for Surgical Services, and Clinical Director of the Breast Program, funding to support "Reducing Re-excisions for Breast Conserving Therapy." In addition, **Lajos Pusztai, MD, DPhil**, has received an award from the BCRF to fund "Characterization of Intra-tumor Heterogeneity and Immune Infiltration in Breast Cancer and its Clinical Implications." Dr. Golshan is a member of Yale Cancer Center's Cancer Prevention and Control Research Program and Dr. Pusztai is Co-Leader of the Genetics, Genomics, and Epigenetics Research Program.

**Stephanie Halene, MD, PhD**, Chief of Hematology and Associate Professor of Medicine (Hematology), and **Jeffrey Ishizuka, MD, DPhil** (Co-PI), Assistant Professor of Medicine (Medical Oncology), have been awarded a grant from the **Edward P. Evans Foundation** to research the m6A writer METTL3 in the treatment of myelodysplastic syndromes by harnessing the activation of the immune response induced by double-stranded RNA formation. **Dr. Halene** has also received an **R01** from the **NIH** to study the novel role for the m6A epitranscriptome in suppressing aberrant innate immune signaling mediated by endogenous double-stranded RNAs and supporting hematopoietic stem and progenitor cell function. Dr. Halene is a member of the Yale Cancer Center Genomics, Genetics, and Epigenetics


Research Program and Dr. Ishizuka is a member of our Cancer Immunology Research Program.

## Colorectal Cancer Screening Test Use By Race/Ethnicity In CT



[Read More](#)

## Yale Cancer Center Perspective Highlights New Advances for NSCLC



[Read More](#)

## Advanced Endometrial Cancer a Lifesaver at Smilow Cancer Hospital



[Read More](#)

## Socks with Stories: Meriden boy with leukemia helps design non-slip socks for kids in hospital



[Watch Now](#)

## Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors?

**Kelsey Martin, MD**, Assistant Clinical Professor of Medicine (Hematology), has been invited to participate in the **American Society of Hematology (ASH) 2021 Class of the Medical Educators Institute (MEI)**. The ASH MEI program provides hematology faculty with resources to develop new educational materials and a career path in medical education. Dr. Martin will use the opportunity to further develop her project on sex and gender within hematology and oncology in the medical school curriculum under the mentorship of Dr. Carolyn Mazure.

**Yanixa Quinones-Aviles**, a graduate student in the lab of **Mandar Muzumdar, MD, PhD**, Assistant Professor of Medicine (Medical Oncology), has been awarded a **F31 Fellowship** from the **National Cancer Institute** to support her project, "Differential Pathway Engagement and the Biological Consequences of KRAS Variants in Cancer."

**Karl L. Insogna, MD**, Ensign Professor of Medicine (Endocrinology) and a member of Yale Cancer Center's Cancer Signaling Research Program, is the 2021 recipient of the **Frederic C. Bartter Award** from the **American Society for Bone and Mineral Research (ASBMR)**. The award is given to an ASBMR member in recognition of outstanding clinical investigation in disorders of bone and mineral metabolism.

The **Yale SPORE in Lung Cancer** recently announced the recipients of the 2021 Career Enhancement Program and Developmental Research Program Award cycles of funding. These awards aim to educate the next generation of investigators committed to translational research in lung cancer. Awardees are as follows:

**Developmental Research Program Awardees:**


- **Anne Chiang, MD, PhD**, Associate Professor of Medicine (Medical Oncology) and Chief Integration Officer, Smilow Cancer Hospital Network (Developmental Therapeutics) and **Katerina Politi, PhD**, Associate Professor of Pathology and Co-Leader of Cancer Signaling Networks, *Exploring Defects in MHC I Antigen Presentation in SCLC with Acquired Resistance to Immunotherapy*.
- **Veronica Chiang, MD, PhD**, Professor of Neurosurgery, Director of Stereotactic Radiosurgery (Radiobiology & Radiotherapy), **Don Nguyen, PhD**, Associate Professor of Pathology and Medicine (Medical Oncology) and Assistant Cancer Center Director for Research Development (Cancer Signaling Networks), and **Stephanie Robert, MD, PhD**, Resident, *Development of Liquid Biopsy for the Diagnosis of Radiation Necrosis in Lung Cancer Patients Through Single-Cell Analysis of Brain Lesions*.
- **Sanjay Aneja, MD**, Assistant Professor of Therapeutic Radiology (Radiobiology & Radiotherapy), *Deriving Imaging Based Biomarkers for Non-Small Cell Lung Cancer Using Deep Learning*.

**Career Enhancement Program Awardees:**

- **Luisa Escobar-Hoyos, MSc, PhD**, Assistant Professor of Therapeutic Radiology (Radiobiology & Radiotherapy), *RNA Splicing as a Novel Therapeutic Target in Lung Cancers with Mutant p53* (Mentors: Katerina Politi, Sarah Goldberg)
- **Thomas Hayman, MD, PhD**, Assistant Professor of Therapeutic Radiology (Radiobiology & Radiotherapy), *PLK4 Inhibition as a*

*Strategy to Enhance the Non-Small Cell Lung Cancer Radiation Response* (Mentors: Joseph Contessa, Megan King)


- **Yansheng Liu, PhD**, Assistant Professor of Pharmacology (Cancer Signaling Networks), *Phosphoproteomic Analysis of TKI Drug*



[Read More](#)



**Join Smilow Cancer Hospital on Facebook**



Ellen F. Foxman, MD, PhD, Assistant Professor of Laboratory Medicine and of Immunobiology and a member of Yale Cancer Center's Cancer Signaling Networks Research Program, has been named a 2021 Rita Allen Foundation Scholar. The foundation celebrates early-career leaders in the biomedical sciences whose research holds exceptional promise for revealing new pathways to advance human health. Dr. Foxman will receive a five-year research grant to study the ability of the innate immune system to provide protection against infections.



[Read More](#)

Recently on Yale Cancer Answers, Dr. Edward Snyder explained the role of transfusion oncology in the care of patients

Signaling Networks), *Phosphoproteomic Analysis of TKI Drug Response and Resistance in Lung Cancer* (Mentors: Don Nguyen, Katerina Politi)

- **Rachel Perry, PhD**, Assistant Professor of Cellular & Molecular Physiology and Medicine (Endocrinology) (Cancer Signaling Networks), *Precision Medicine Immunometabolic Approaches to Lung Cancer* (Mentors: Katerina Politi, Nikhil Joshi)

The **Cancer Signaling Networks Research Program** welcomes **Peter Humphrey, MD, PhD**, Professor of Pathology and Director of Genitourinary Pathology. Dr. Humphrey has an extensive background in genitourinary cancer research and has published extensively in prostate pathology and prostate cancer research. In addition to teaching residents and fellows, Dr. Humphrey has demonstrated leadership in program development by starting a genitourinary and renal pathology fellowship program together with Dr. Gilbert Moeckel.



## Diversity, Equity, and Inclusion

Yale University has released a new consolidated **Policy Against Discrimination and Harassment** for university employees, which sets out in one place the definitions of discrimination, harassment, and retaliation applicable to all students, faculty, and staff. In addition, a new website has launched highlighting all **Accessibility Resources at Yale** for students, faculty, staff, and visitors. This website gives a comprehensive description of the resources available to provide people with disabilities equal access to and full participation in the university's programs and activities. Any accessibility concerns may be submitted via the **Report a Disability-Related Accessibility Barrier Form**.

## NCCN Opportunities

One of the benefits of Yale Cancer Center/Smilow Cancer Hospital's institutional membership in the National Comprehensive Cancer Network (NCCN) is that all staff employed at NCCN Member Institutions receive free registration to the following virtual events.

The **NCCN 2021 Virtual Congress: Hematologic Malignancies™** will take place October 14 – 16, 2021, and will feature a new format with three days of interactive presentations for a variety of hematologic malignancies. You can register for free by using your institution email address and the code

MI2021: [NCCN.org/hem2021-summary](https://www.nccn.org/hem2021-summary).

The **NCCN 2021 Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™** will take place October 8, 2021. This virtual

transfusion oncology in the care of patients with cancer, and how blood is stored for potential use. Tune in on Connecticut Public Radio or download our podcast from iTunes.



[Read More](#)

Learn more about third-dose COVID-19 vaccine eligibility for those with weakened immune systems, including active or recent treatment of cancer. If you or your loved ones are eligible, self-scheduling is now open.

## COVID-19 Vaccination Update

YaleNewHavenHealth

[Read More](#)

"Often times I try to see if new medicines are useful against various sarcomas or thyroid cancers to help my patients." — Dr. Hari Deshpande discusses how clinical trials are an integral part of his research focus.



program provides hematology/oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. You can register for free by using your institution email address and the code MI2021: [NCCN.org/hem-nursing](https://www.nccn.org/hem-nursing).

## Employee Profile: Janine Franklin, ACA

Janine Franklin, Ambulatory Care Associate (ACA), has been caring for patients in one capacity or another for over 30 years. She started in a nursing home where she worked for 18 years before moving to a private duty job, and then to the Hospital of Saint Raphaels, and as of six years ago she has been caring for patients at the Smilow Cancer Hospital Care Center in North Haven in the outpatient infusion clinic.

Before a patient even sets foot in the clinic, Janine has made sure that everything is set up and ready to go. She then passes out assignments for the day, including which ACAs will be assigned to which nurse. On an average day, there may be 30-45 patients receiving some form of treatment in her unit. Once the first patient arrives, Janine is in constant communication with the team, including the Smilow ambassadors, social workers, and dietitians, and is always checking in with her nurse to see if there is anything that they or the patient needs. She also performs vital signs and EKGs as needed, and is responsible for boxing up the medical waste from chemotherapy to be disposed of.

“My goal is to keep things running smoothly every day, and I am always looking for ways to make things quicker and easier for the patient so they don’t have to wait unnecessarily,” said Janine. “Some patients I have seen every six months for the last six years, and I always try to be cheerful and helpful. It can be challenging at times, but I always say that anyone working in oncology is here for a reason. We are the right people for this job.”

Janine received a Smilow Luminary Award of Excellence in Patient Care in 2020, which honors people who consistently exceed performance expectations and deliver high-quality cancer care for patients, families, and the health system. Paula Pike, RN, BSN, MSN/A, MBA/HC, NE-BC, Clinical Program Manager for the Smilow Cancer Hospital Network commented, “Janine always puts our patients first. When asked why she works in oncology she responded, ‘it’s rewarding.’ Janine brings compassion and laughter to our patients and our team.”



[Watch Now](#)

A long-standing partner of Smilow Cancer Hospital, Big Y World Class Market, Branford, recently presented \$10,000 to our Breast Cancer Program supporting personalized care for patients and their families. Pictured (L-R) Maureen McManus Hackett, YNH, and Mary Ann Granata, Store Manager, along with her staff. Thank you Big Y!



[Read More](#)

“I am focused on developing new clinical trials and opening studies for patients with hepatobiliary cancers and that is very rewarding.”— Dr. Stacey Stein on why her research efforts are so important to clinical care for liver cancer.



[Watch now](#)

The Phase I Clinical Trial Infusion Center at Smilow Cancer Hospital opened five years ago and its team of dedicated highly-trained staff have worked together to create a faster,

## Recent Publications

Irwin, M. L., Lowry, D., Neuhouser, M. L., Ligibel, J., Schmitz, K., Patterson,

R. E., Golditz, G., Li, F., & Nebeling, L.

**Transdisciplinary Research in Energetics and Cancer early career investigator training program: first year results.**

*Translational behavioral medicine*, 11(2), 549–562.

[Read More](#)

Burtness B.

**Treatment De-Intensification for Head and Neck Cancer.**

Practice Update, August 05, 2021.

[Read More](#)

Hung P, Cramer LD, Pollack CE, Gross CP, Wang SY.

**Primary Care Physician Continuity, Survival, and End-of-Life Care Intensity.**

*Health Services Research*, Online ahead of Print

[Read More](#)

Wang M, Herbst RS, Boshoff C.

**Toward Personalized Treatment Approaches For Non-Small-Cell Lung Cancer.**

*Nature Medicine*, Online ahead of print.

[Read More](#)

Podany P, Gilani SM.

**Hyalinizing Trabecular Tumor: Cytologic, Histologic and Molecular Features and Diagnostic Considerations.**

*Annals of Diagnostic Pathology*, Online ahead of print.

[Read More](#)

Gould Rothberg BE, Canavan ME, Mun S, Sedghi T, Carafeno T, Raucci M, Dest V, Sinanis N, Gross CP, Adelson KB.

**Impact of a Dedicated Cancer Urgent Care Center on Acute Care Utilization.**

*JCO Oncology Practice*, Online ahead of print.

[Read More](#)

Torabi SJ, Su-Velez BM, Kasle DA, Yarbrough WG, St John M, Judson BL.

**Assessing Human Papillomavirus Awareness and the Role of Oropharyngeal Squamous Cell Carcinoma Education on Improving Intention to Vaccinate.**

*The Laryngoscope*, Online ahead of print.

[Read More](#)

Hasan NM, Sharma A, Ruzgar NM, Deshpande H, Olino K, Khan S, Ahuja N.

**Epigenetic Signatures Differentiate Uterine and Soft Tissue Leiomyosarcoma.**

*Oncotarget*, 12(16):1566-1579.

[Read More](#)

Wei J, Ishizuka JJ.

**Going viral: HBV-specific CD8 + Tissue-resident Memory T Cells Propagate Anti-tumor Immunity,**

*Immunity*, 54(8):1630-1632.

[Read More](#)

broader pipeline for Phase I clinical trials. Dr. Paul Eder, Dr. Patricia LoRusso, and the entire team have not only significantly increased the number of immune-based therapies and other treatments entering Phase I trials, but also dramatically shortened the timeline for introducing those therapies to patients for whom time is of the essence.



[Read More](#)

Join Smilow Integrative Medicine Program's Bill Banick, Certified Yoga Instructor, as he guides you through a chair-based exercise that is gentle and easy to follow, focused on building strength and flexibility.



[Read More](#)

"Our team at the Smilow Cancer Hospital Care Center in Orange brings innovative Smilow cancer care to our patients in a small, intimate setting where our patients personally know each team member. We're proud to provide our patients with access to a National Cancer Institute- designated Comprehensive Cancer Center and its clinical trials and advances. Our physicians coordinate with our colleagues in New Haven to ensure all treatment options are reviewed through multidisciplinary tumor boards, and each patient receives personalized cancer care." — Dr. Johanna LaSala, Medical Director of the Smilow Cancer Hospital Care Center in Orange, pictured with Dr. Kelsey Martin.



Bossuyt V, Lau R, Young B, Howe JG, Zhao F, Leyland-Jones B, Du L, Foli T, Hatzis C, Symmans WF.

### **Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer.**

*Clinical Chemistry*, Online ahead of print.

[Read More](#)

Tymon-Rosario J, Siegel ER, Bellone S, Harold J, Adjei N, Zeybek B, Mauricio D, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Azodi M, Schwartz PE, Fader AN, Santin AD.

### **Trastuzumab Tolerability in the Treatment of Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress HER2/neu.**

*Gynecologic Oncology*, Online ahead of print.

[Read More](#)

Dasari K, Somarelli JA, Kumar S, Townsend JP.

### **The Somatic Molecular Evolution of Cancer: Mutation, Selection, and Epistasis.**

*Progress in Biophysics and Molecular Biology*, Online ahead of print.

[Read More](#)

Jin L, Youngblood MW, Gupte TP, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera SM, Mishra-Gorur K, Blondin NA, Gorelick E, Omay SB, Pointdujour-Lim R, Judson BL, Alperovich M, Aboian MS, McGuone D, Gunel M, Erson-Omay Z, Fulbright RK, Moliterno J.

### **Type of Bony Involvement Predicts Genomic Subgroup in Sphenoid Wing Meningiomas.**

*Journal of Neuro-Oncology*, Online ahead of print.

[Read More](#)

Bleicher RJ, Moran MS, Ruth K, Edge SB, Dietz JM, Wilke LG, Stearns V, Kurtzman SH, Klein J, Yao KA.

### **ASO Visual Abstract: The Impact of Radiotherapy Delay in Breast-Conservation Patients Not Receiving Chemotherapy and the Rationale for Dichotomizing the Radiation Oncology Time-Dependent Standard into Two Quality Measures.**

*Annals of Surgical Oncology*, Online ahead of print.

[Read More](#)

Chen D, Simons M.

### **Emerging Roles of PLC $\gamma$ 1 in Endothelial Biology.**

*Science Signaling*, 14(694):eabc6612.

[Read More](#)

Shallis RM, Zeidan AM.

### **Management of the Older Patient with Myelodysplastic Syndrome.**

*Drugs & Aging*, Online ahead of print.

[Read More](#)

Bewersdorf JP, Tallman MS, Stahl M.

### **Maintenance Therapies in Acute Myeloid Leukemia: The Renaissance of an Old Therapeutic Concept.**

*Current Opinion in Oncology*, Online ahead of print.

[Read More](#)



[Read More](#)

## **Follow Yale Cancer Center on Twitter**

Follow us on [twitter](#)



"Instead of waiting for our culture to change, we [@SmilowCancer] keep working to change our culture. Very few people are hesitant about screening when you talk to them," Dr. Xavier Llor, Director of Screening & Prevention.



New data from @SmilowCancer led by @BEGouldRothberg shows that establishing a cancer-specific urgent care center decreased ER utilization among oncology patients on active therapy.



"We have 9 new drugs that have been approved since 2017 for AML, so it's definitely a situation that has been improving significantly." @Dr\_AmerZeidan on the rare leukemia a CT firefighter was diagnosed with following his tragic death.



"Expansion & further investment in collaborative research are essential to continue our journey towards a cure."—@DrRoyHerbstYale w/Dr. Meina Wang discuss their report about advances in #NSCLC in @NatureMedicine.



A new meta-analysis led by @DrRoyHerbstYale in @FrontiersIn suggests superiority of #cancer immunotherapy regimens versus #chemotherapy as first-line treatment of #NSCLC with #PDL1 for survival, objective response, & safety.



A new review by @ValentinaRangAn and @StacyMalaker in @ACSPublications summarizes the methods, challenges, and new opportunities

Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL.

### **Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors.**

*Pancreas*, 50(6):890-894.

[Read More](#)

Kunitomo Y, Bade B, Gunderson CG, Akgün KM, Brackett A, Cain H, Tanoue L, Bastian LA.

### **Racial Differences in Adherence to Lung Cancer Screening Follow-Up: A Systematic Review and Meta-Analysis.**

*Chest*, Online ahead of print.

[Read More](#)

Ren M, Zhang Q, Zhang S, Zhong T, Huang J, Ma S.

### **Hierarchical Cancer Heterogeneity Analysis Based on Histopathological Imaging Feature.**

*Biometrics*, Online ahead of print.

[Read More](#)

---

## **Funding and Award Opportunities**

### **AACR Clinical Oncology Research (CORE) Training Fellowships**

This grant program pertains to the following fellowships: AACR-AstraZeneca Clinical Immuno-oncology Research Training Fellowships and AACR-Bayer Clinical Oncology Research Training Fellowships and is designed to provide an effective industry-academic clinical practicum with a unique training opportunity to develop academic clinicians in drug development.

**Application Deadline:** August 31, 2021

[Read More](#)

### **Pfizer Relapsed/Refractory Multiple Myeloma Competitive Grant Program**

This award is focused on increasing healthcare professional understanding of BCMA-directed therapies (BCMAxCD3 bi-specifics; BCMA-ADC; BCMA – CAR-T cells) in relapsed/refractory multiple myeloma.

**Application Deadline:** August 31, 2021

[Read More](#)

### **Yale Cancer Center 2022 Team Challenge Award**

An internal grant program focused on advancing the work of teams who seek to address a fundamental research priority that aligns and/or has the potential to successfully extend YCC strategic goals.

**Letter of Intent Due:** September 1, 2021

[Read More](#)

### **Hope Foundation for Cancer Research 2021 SWOG Coltman Fellowship Program Request for Applications A Career Development Program for Early Career Investigators**

The primary purpose of the Fellowship is to engage outstanding early-career investigators from SWOG-affiliated institutions in learning clinical trial methodology within an academic and network group environment that will lead to independent clinical research

**Application Deadline:** September 1, 2021

methods, challenges, and new opportunities associated with studying enigmatic mucin domains.



Congratulations to Dr. Michael Alperovich, [@CeceCalhounMD](#)

and [@AileenIlianaPhD](#) selected as 2021 Yale Center for Clinical Investigation Scholars.



Congratulations to

[@GeorgeGoshuaMD](#) selected as the recipient of 2021 [@YaleCancer](#) Bernard G. Forget Scholar given to a deserving individual who is transitioning from a fellowship to an academic career in [#hematology](#).



Congratulations to

[@YanixaQuinones](#) a PhD student in the [@MuzumdarLab](#), awarded an F31 fellowship from [@NIH](#) [@NCICancerBio](#) to research "Differential pathway engagement and the biological consequences of [#KRAS](#) variants in [#pancreaticcancer](#)."



In collaboration with

[@ProjInKnowledge](#) the series Experts at Your Fingertips focusing on [#MyeloidLeukemia](#) is led by Dr. Nikolai Podoltsev and includes [@SmilowCancer](#) APRN's [@lisa\\_barbarotta](#) and Julie Baker. Watch now!



Congratulations to [@EllenFoxman](#) named one of five 2021 Rita Allen

Foundation Scholars for being an early-career leader in the biomedical sciences. The scholars will receive research grants.

---

## **Calendar**

### **Yale Cancer Answers**

**August 22; 7:30 PM**

**NPR**

*Recent Treatment Advances in Small Cell*

*Lung Cancer*

**Anne Chiang, MD, PhD**

[Learn More](#)

### **Yale Cancer Center Seminar**

**August 9; 4:00 PM**

*Targeting Innate Immunity and Angiogenesis to Improve Response and Minimize Toxicity*

**Application Deadline:** September 1, 2021

[Read More](#)

### Early Detection Research Network FOAs

The mission of the EDRN is to discover, develop and validate biomarkers and imaging methods to detect early-stage cancers and to assess risk for developing cancer, and to translate these biomarkers and imaging methods into clinical tests. There are three specific units with EDRN:

- Clinical Validation Centers (U01)
- Data Management and Coordinating Center (U24)
- Biomarker Characterization Centers (U2C)

**Application Deadlines:** September 9, 2021

[Read More](#)

### Time-Sensitive Obesity Policy and Program Evaluation (R01)

This FOA establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors and/or weight outcomes to prevent or reduce obesity.

**Application Deadline:** September 22, 2021

[Read More](#)

### Charles H. Hood Foundation: Child Health Research Awards Program

This award is to support newly independent faculty, provide the opportunity to demonstrate creativity, and assist in the transition to other sources of research funding.

**Application Deadline:** September 22, 2021

[Read More](#)

### NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54)

This RFA aims to facilitate institutions in building a community of scientists by recruiting and supporting a cohort of early-career faculty who have demonstrated a commitment to diversity and inclusive excellence.

**Application Deadline:** September 24, 2021

[Read More](#)

### National Comprehensive Cancer Network & Eli Lilly Biomarker Driven Therapy in Lung and Thyroid Cancers

The NCCN and Eli Lilly are seeking proposals to improve patient care and outcomes in lung and thyroid cancers. Multiple factors contribute to the complexity of treating these diseases, including stage and histology, personalization of systemic therapy based on molecular profiles, patient factors, and therapeutic landscape.

**Application Deadline:** September 28, 2021

[Read More](#)

### Cancer Research Institute Irvington Postdoctoral Fellowship Program

Supports qualified young scientists at leading universities and research centers around the world who wish to receive training in fundamental immunology or cancer immunology. Proposals should include studies that directly impact our understanding of the immune system's role in cancer.

**Application Deadline:** October 1, 2021

[Read More](#)

### Technology Development for Single Molecule Protein Sequencing (R01)

*to Improve Response and Minimize Toxicity*

*to Checkpoint Inhibitors in Melanoma*

**Thuy Tran, MD, PhD**

[Learn More](#)

### Therapeutic Radiology Grand Rounds

**August 26; 9:00 AM**

*Dermatologic Toxicities from Systemic Cancer Therapy and Radiotherapy: Lessons Learned from Yale Onco-Dermatology Program*

**Jonathan Leventhal, MD**

[Learn More](#)

### Yale Cancer Answers

**August 29; 7:30 PM**

**NPR**

*Adolescents and Young Adults with Sickle Cell Disease*

**Cece Calhoun, MD, MPH, MBA**

[Learn More](#)

### IMP Thesis Defense

**September 2; 12:00 PM**

*Modulation of T Cell Response Hierarchy by Coinhibition and Costimulation in Cancer Immunotherapy*

**Yu Zhang, MD**

[Learn More](#)

### Center for GI Cancers Weekly Seminar

**September 2; 4:15 PM**

[Learn More](#)

---

### Submissions

Please submit your recent publications, awards, and grant announcements to:

[Renee Gaudette](#)

Director, Public Affairs and Communications

### **Technology Development for Single-Molecule Protein Sequencing (R01)**

This FOA solicits grant applications to catalyze major advances in single-molecule protein sequencing and single cell proteome analysis through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost, and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.

**Application Deadline:** October 1, 2021

**Read More**

### **The Role of Work in Health Disparities in the U.S. (R01)**

The purpose of this FOA is to support innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities, and how work functions as a social determinant of health.

**Application Deadline:** October 5, 2021

**Read More**

### **Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01)**

Through this FOA, the NCI invites R01 grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of these modalities in the characterization of therapy response and/or emergence of treatment resistance.

**Application Deadline:** October 5, 2021

**Read More**

### **Molecular Imaging of Inflammation in Cancer (R01)**

The purpose of this FOA is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation *in vivo*.

**Application Deadline:** October 5, 2021

**Read More**

### **Cancer Target Discovery and Development (CTD2) (U01)**

Through this FOA, the NCI will support the program Cancer Target Discovery and Development. CTD2 is focused on efforts that advance cancer research by bridging the knowledge gap between the large volumes of comprehensive molecular characterizations of many cancer types and studies of the underlying etiology of cancer development, progression, and/or metastasis.

**Application Deadline:** October 6, 2021

**Read More**

### **Metabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01)**

The NCI invites research grant applications for transdisciplinary studies that will enhance our knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation and increased cancer risk as part of the Metabolic Dysregulation and Cancer Risk Program. Through this FOA, the Metabolic Dysregulation and Cancer Risk Program will focus on metabolic dysregulation as the key process linking obesity with cancer risk.

**Application Deadline:** October 6, 2021

**Read More**

[Read More](#)

**Coordinating Center for the Metabolic Dysregulation and Cancer Risk Program: A Transdisciplinary Approach to Obesity-Associated Cancer Research (U24)**

Through this FOA, the NCI will support a Coordinating Center to facilitate coordination across the consortium of multiple individual research project grants for the Metabolic Dysregulation and Cancer Risk Program whose overarching goal is to enhance our knowledge of the dynamics, and underlying mechanisms, that link obesity, metabolic dysregulation, and increased cancer risk.

**Application Deadline:** October 6, 2021

[Read More](#)

**Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54)**

The purpose of this FOA is to solicit applications for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54). The overall goal of the CAP-IT Program is to establish an agile and effective network infrastructure to undertake collaborative research focusing on precision cancer prevention and interception, with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations.

**Application Deadline:** October 7, 2021

[Read More](#)

**Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC) (U24)**

The purpose of this FOA is to solicit Applications for the Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC) (U24). The overall goal of this FOA and the companion FOA (U54 CAP-IT Specialized Centers, RFA-CA-21-038) is to establish an agile and effective network infrastructure to undertake collaborative research focusing on precision cancer prevention and interception, with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations.

**Application Deadline:** October 7, 2021

[Read More](#)

**Program on the Origins of Gastroesophageal Cancers (R01)**

This FOA is to request applications for the Program on the Origins of Gastroesophageal Cancers (R01). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level.

**Application Deadline:** October 8, 2021

[Read More](#)

**Coordinating Center for the Program on the Origins of Gastroesophageal Cancers (U24)**

This FOA is to request applications for the Coordinating Center, Program on the Origins of Gastroesophageal Cancers (U24). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research

understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level.

**Application Deadline:** October 8, 2021

**Read More**

### **CRI Irvington Postdoctoral Fellowship to Promote Racial Diversity**

CRI invites applications from candidates who identify as Black or African American, Hispanic or Latino/a American, or American Indian or Alaska Native. CRI is seeking hypothesis-driven, mechanistic studies in both immunology and tumor immunology that aim to directly impact our understanding of the immune system's role in cancer.

**Application Deadline:** October 21, 2021

**Read More**

### **Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54)**

The purpose of this FOA is to solicit applications for U54 Research Centers to form the Radiation Oncology-Biology Integration Network (ROBIN). The cadre of ROBIN Centers created through this FOA will establish an agile and effective national radiation oncology network infrastructure that collectively address critical hypothesis-based translational research knowledge gaps on the biological basis of responses in cancer patients who undergo radiation treatments.

**Application Deadline:** November 1, 2021

**Read More**

### **NCI Research Specialist Awards (Laboratory-based Scientist) Award (R50)**

This FOA invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists and is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators.

**Application Deadline:** November 1, 2021

**Read More**

### **NCI Research Specialist (Core-based Scientist) Award (R50)**

This FOA invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists and is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators.

**Application Deadline:** November 1, 2021

**Read More**

### **Cancer Research Institute Technology Impact Award**

These grants aim to encourage collaboration between technology developers and clinical cancer immunologists and to generate the proof-of-principle of a novel platform technology in bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents

and assays, or other relevant technologies that can enable clinician scientists to generate deeper insights into the mechanisms of action of effective or ineffective cancer immunotherapies.

**Letter of Intent Due:** November 15, 2021

**[Read More](#)**

### **Understanding Oral HPV Infection, Acquisition, and Persistence in People Living with HIV (R01, R21)**

The purpose of these FOAs are to solicit research to better understand the epidemiology and biology of oral HPV infection, its acquisition and persistence, in people living with HIV and elucidate the initial mechanisms related to HPV-associated oral and oropharyngeal cancers and warts in the context of HIV.

**Application Deadline:** November 18, 2021

**[Read More](#)**

### **The Hope Foundation for Cancer Research SEED Fund for SWOG Early Exploration and Development 2021**

These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early stage clinical trials), small, self-contained research projects, or development of research methodology/technology. \$50,000

**Application Deadline:** December 1, 2021

**[Read More](#)**